ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Instadose Pharma Corp. and Encourages Investors with Losses of $100,000 to Contact the Firm
Los Angeles, California--(Newsfile Corp. - December 3, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Instadose Pharma Corp. ("Instadose" or "the Company") (OTC: INSD) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The SEC announced a temporary suspension in the trading of Instadose securities on November 23, 2021. The SEC based this action on concerns about both the accuracy and adequacy of information about the Company available to the market. The regulators noted the Company's shares have jumped in price and trading volume in a manner not supported by its assets and financials. There are also concerns about trading associated with individuals related to a person with control of the Company and the operations of the Company's Canadian subsidiary. Based on these facts, shares of Instadose dropped by 13% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/106633